Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes (PRIME)

1. november 2026 opdateret af: Maja Guberina, University Hospital, Essen

High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes; PRIME: P: Precision R: Radiosurgery I: Intervention M: Minimal Invasive Surgical Approach E: EYESIGHT

High-precision radiosurgery followed by minimally invasive surgical approach in patients with high-prominence uveal melanomas: modern radiation techniques and outcomes. Evaluation of outcome regarding multiparametric parameters and co-factors

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

The aim here is to prospectively evaluate modern technical standards. The aim of this study is to assess the influence of the updated basic diagnostics and high-resolution diagnostics for radiation planning and the new technical therapy standards (therapy options in application: volume modulated rapid arc technique (VMAT) / online arc technique (VMAT) / online onboard image-guidance (IGRT), by means of the newly established Clinic for Radiation Therapy 2019-2021) depending on known prognostic parameters for quality assurance of the long-term outcome (overall survival, local tumor control). This will lay the basis for standardizing treatment parameters as far as possible, but also to introduce improvements in the treatment of future patients.

Scientific background (state of research (with literature references) and

Derivation of the research question (rationale)):

The eye can be affected by several neoplastic processes, which can lead either primarily or secondary to systemic metastasis. The most common primary tumors of the eye include conjunctival melanoma and uveal melanoma. Metastases from systemic malignant diseases, particularly of the breast and lungs, can also affect the eye.

A combination of ophthalmologic examination, MRI and additional tests and cytologic/histopathologic evaluation leads to an accurate diagnosis.

Depending on the tumor manifestation, treatment consists of a multimodal concept. In the case of uveal melanomas and the aim of preserving the globe and and visual acuity preservation, radiotherapy is one of the most important treatment modalities that can be applied.

In the last 20 years, radiotherapy has developed rapidly away from two-dimensional modulated, three-dimensional techniques. But here too the high level of technical diversity in radiotherapy and ever newer technical innovations, there is a broad spectrum of radiotherapy. Standard therapy can be performed using modern devices, the high-precision stereotactic linear accelerators (irradiation devices), can be safely further optimized. This is to be tested in the Department of Radiotherapy.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

250

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Essen, Tyskland
        • Rekruttering
        • University Hospital Essen
        • Kontakt:
      • Essen, Tyskland, 45147
    • Germany / NRW
      • Essen, Germany / NRW, Tyskland, 45147
        • Rekruttering
        • Department for Radiotherapy, University Hospital Essen, National Center for Tumor Diseases (NCT) West
        • Kontakt:
        • Kontakt:
          • Ina Grübel
        • Ledende efterforsker:
          • Maja Guberina, PD Dr. med. (MD)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Inclusion Criteria:

- Resectability, high-prominent and high risk uveal melanoma

Exclusion Criteria:

  • EOE
  • lux defect (If a medical report notes a "lux defect" alongside this, it refers to a deficit in light perception (from the Latin lux for light). It means the eye's ability to sense light, darkness, or light direction is impaired)

Beskrivelse

Inclusion Criteria:

  • Functional Resectability,
  • Technical Resectability
  • high-prominent uveal melanoma

Exclusion Criteria:

  • EOE
  • At least in part remaining eye function that can be saved

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Local control
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Local control

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual acuity:
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual function assessed separately for each eye. Visual acuity:

decimal scale,range 2,0 - 0,01: decimal acuity scale

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Quality of Life, ophthalmic cancer-specific quality of life
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Quality of Life, ophthalmic cancer-specific quality of life

1) EORTC QLQ-OPT30 (ophthalmic cancer-specific quality of life): Scores range from 0-100; higher scores indicate greater visual impairment, ocular symptoms, and functional difficulties.

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Progression Free Survival
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Progression Free Survival

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Overall Survival
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Overall Survival

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual acuity:
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual function assessed separately for each eye. Visual acuity:

decimal scale,range 2,0 - 0,01: decimal acuity scale; furthermore, 1.Count-fingers, 2.hand-motion and 3.light-perception categories are recorded separately when acuity cannot be quantified: for each item: value yes / no

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Visual field
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Visual field: Automated perimetry, Visual Field Index (VFI, %): 0 % - 100%,

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Quality of Life general quality of life
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

EORTC QLQ-C30 (general quality of life): Scores range from 0-100; A) higher scores indicate better functioning/global quality of life B) symptom scores: indicate greater symptom burden on symptom scales.

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Function: Retinal Nerve Fiber Layer
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Optical coherence tomography (OCT): Peripapillary retinal nerve fiber layer (RNFL) thickness, measured in µm and classified in percentiles (regarding normal values)

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Cornea
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

corneal outcome: thickness measured in µm

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Cornea
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Corneal outcome modified Stocker's classification:

category 0 No damage no injury category 1 corneal guttae without epithelial or stromal edema. category 2 corneal guttae with epithelial or stromal edema. category 3 corneal edema associated with scar formation. category 4 corneal opacification with neovascularization, modified Stocker's classification

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.
Corneal overall outcome classification
Tidsramme: At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

category 0 No corneal-ulcus category 1 Irregular punctate epithelial defects category 2 Non-healing epithelial defects / persistent epithelial defect (PED) category 3 Ulcer perforation

At 3 months, every 6 months up to 24 months, and annually thereafter up to 60 -120 months.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. september 2019

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

30. juni 2032

Datoer for studieregistrering

Først indsendt

18. oktober 2026

Først indsendt, der opfyldte QC-kriterier

1. november 2026

Først opslået (Faktiske)

3. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 21-10377-BO

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

dependent on the project

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .